INT173878

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 32
Total Number 34
Disease Relevance 9.35
Pain Relevance 3.55

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (ACAN) cell adhesion (ACAN) proteinaceous extracellular matrix (ACAN)
Anatomy Link Frequency
chondrocytes 7
margin 2
internal 2
body 2
T-cell 1
ACAN (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 231 99.88 Very High Very High Very High
cytokine 140 98.88 Very High Very High Very High
Arthritis 535 96.48 Very High Very High Very High
Osteoarthritis 387 93.64 High High
rheumatoid arthritis 55 85.44 High High
spinal inflammation 5 84.88 Quite High
Inflammation 73 73.84 Quite High
Pain 43 60.76 Quite High
COX-2 inhibitor 1 59.52 Quite High
backache 66 51.40 Quite High
Disease Link Frequency Relevance Heat
Dermal Scarring 192 100.00 Very High Very High Very High
Obesity 105 99.12 Very High Very High Very High
Osteoarthritis 453 98.64 Very High Very High Very High
Juvenile Chronic Polyarthritis 450 96.48 Very High Very High Very High
Retina Disease 8 94.72 High High
Death 11 86.24 High High
Rheumatoid Arthritis 58 85.44 High High
Apoptosis 33 85.24 High High
Low Back Pain 71 84.88 Quite High
Alzheimer's Dementia 2 83.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Its molecules are continually being broken down by proteinases such as the matrix metalloproteinases (MMPs) and aggrecanases, which are also synthesized by disc cells [29-31].
Gene_expression (synthesized) of aggrecan associated with metalloproteinase
1) Confidence 0.75 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165040 Disease Relevance 0.08 Pain Relevance 0.10
In order to identify chondrocytes, the expression of type II collagen and aggrecan mRNAs and proteins as a chondrogenic markers were determined by RT-PCR and Western blot analysis.
Gene_expression (expression) of aggrecan in chondrocytes
2) Confidence 0.75 Published 2006 Journal Journal of Korean Medical Science Section Body Doc Link PMC2733955 Disease Relevance 0.18 Pain Relevance 0.15
This dosage also induced the expression of genes encoding aggrecan, COX-2 and MMP-13 in obese patients.
Gene_expression (expression) of aggrecan associated with obesity
3) Confidence 0.75 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911905 Disease Relevance 1.17 Pain Relevance 0.09
Expression levels of AGC1, SOX9 and COL2 were studied as chondrogenic markers, while COL1 was studied as a dedifferentiation marker [34,35,49,50].
Gene_expression (Expression) of AGC1
4) Confidence 0.69 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911888 Disease Relevance 0.08 Pain Relevance 0
We are therefore currently looking into the underlying molecular mechanisms regulating AGC1 and COL2 expression in both conditions.
Gene_expression (expression) of AGC1
5) Confidence 0.69 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911888 Disease Relevance 0.08 Pain Relevance 0
Coating had four treatment groups (collagen I coating, aggrecan coating, no coating control and no coating passage), whereas passage had five treatment groups (P0 to P4).
Gene_expression (coating) of aggrecan
6) Confidence 0.65 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2212577 Disease Relevance 0 Pain Relevance 0
However, processing events removing the spacer region might generate a more promiscuous and destructive activity capable of disaggregating aggrecan–hyaluronan complexes through IGD proteolysis, resulting in the loss of aggrecan from the tissue.
Gene_expression (proteolysis) of aggrecan
7) Confidence 0.65 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175049 Disease Relevance 0.16 Pain Relevance 0.03
A 44 bp insertion of a polyA29 tract flanked by a 15 bp duplication (A29GGA AGC AAC AGG ATG; RPGRIP1 insertion) was identified in the presumptive exon 2 of RPGRIP1.
Gene_expression (insertion) of AGC
8) Confidence 0.65 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2779058 Disease Relevance 0.74 Pain Relevance 0
Several studies have already shown that chondrocytes are tonicity responsive [7-9] and react with changes in matrix synthesis [4,8,10,11], but focused on aggrecan (AGC1) core protein mRNA levels, AGC1 promoter activity and GAG production.
Gene_expression (levels) of AGC1 in chondrocytes
9) Confidence 0.60 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911888 Disease Relevance 0.16 Pain Relevance 0.08
Several studies have already shown that chondrocytes are tonicity responsive [7-9] and react with changes in matrix synthesis [4,8,10,11], but focused on aggrecan (AGC1) core protein mRNA levels, AGC1 promoter activity and GAG production.
Gene_expression (levels) of AGC1 in chondrocytes
10) Confidence 0.60 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911888 Disease Relevance 0.16 Pain Relevance 0.08
To demonstrate that the hypertonicity-induced chondrogenic marker expression was indeed mediated by NFAT5, we used RNAi to confirm that knockdown of NFAT5 significantly inhibited hypertonic induction of its own transcription as discussed before, significantly suppressed the tonicity-mediated induction of known NFAT5 targets, and, most importantly, significantly eliminated the hypertonicity-mediated mRNA expression of chondrogenic marker genes (COL2, AGC1, SOX9 and COL1).


Gene_expression (expression) of AGC1
11) Confidence 0.60 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911888 Disease Relevance 0.06 Pain Relevance 0.03
Human osteoarthritic explants treated with glucosamine-3-sulphate showed down regulated expression of aggrecan and aggrecanase mRNA, suggesting that glucosamine might reduce enzymatic breakdown of the extra-cellular matrix (11,12).
Gene_expression (expression) of aggrecan associated with osteoarthritis
12) Confidence 0.58 Published 2008 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2529383 Disease Relevance 0.23 Pain Relevance 0.07
Expression levels of AGC1, SOX9 and COL2 were studied as chondrogenic markers, while COL1 was studied as a dedifferentiation marker [34,35,49,50].
Gene_expression (levels) of AGC1
13) Confidence 0.53 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911888 Disease Relevance 0.08 Pain Relevance 0
Interestingly, AGC1 seems to be more stably expressed in cultures maintained at 280 mOsm compared with 380 mOsm, with a lower overall expression in the former condition.
Gene_expression (expressed) of AGC1
14) Confidence 0.53 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911888 Disease Relevance 0.20 Pain Relevance 0
In expanded P3 chondrocytes in physiological culture, AGC1 levels were still higher than in unpassaged P0 chondrocytes cultured under the standard culture conditions (280 mOsm).
Gene_expression (levels) of AGC1 in chondrocytes
15) Confidence 0.52 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911888 Disease Relevance 0.23 Pain Relevance 0.12
A statistically significant (P < .05) differential expression and a fold change of more than 2 were determined between keloid margin and internal control biopsy samples for 10 genes, including ACAN, ASPN, C5orf13, HIF1A, IGFBP7, INHBA, LGALS1, PTN, SERPINH1, and TNFAIP6 (Table 5).
Gene_expression (expression) of ACAN in internal associated with dermal scarring
16) Confidence 0.44 Published 2010 Journal Eplasty Section Body Doc Link PMC2851107 Disease Relevance 0.23 Pain Relevance 0
Analysis of expression of traditional marker genes in human normal IVD samples (Figure 5) showed that when compared with AC cells, ACAN and COL2A1 gene expression was significantly lower in normal AF cells (P = 0.0003, and P < 0.0001, respectively) and normal NP cells (P = 0.0018, and P < 0.0001, respectively).
Gene_expression (expression) of ACAN
17) Confidence 0.28 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875656 Disease Relevance 0 Pain Relevance 0
NP cells of the IVD share a common lineage with articular chondrocytes, with both cell types expressing the key chondrocyte genes collagen, type II, alpha 1 (COL2A1), aggrecan (ACAN) and SRY (sex determining region Y)-box 9 (SOX-9) [11].
Gene_expression (expressing) of ACAN in chondrocyte
18) Confidence 0.25 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875656 Disease Relevance 0.07 Pain Relevance 0
The results demonstrated that pre-existing marker genes generally showed the expected pattern of expression, that is high expression of ACAN in NP and AC, high expression of type I collagen in AF compared with NP and AC, and high expression of versican (VCAN) in both NP and AF compared with AC.
Gene_expression (expression) of ACAN
19) Confidence 0.25 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875656 Disease Relevance 0 Pain Relevance 0
AF cells are elongated and fibroblastic in appearance, but retain expression of chondrocyte marker genes, such as type II collagen (COL2A1) and aggrecan (ACAN).
Gene_expression (expression) of ACAN in chondrocyte
20) Confidence 0.25 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875656 Disease Relevance 0.05 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox